Compare FMBH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMBH | CRVS |
|---|---|---|
| Founded | 1865 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1995 | 2016 |
| Metric | FMBH | CRVS |
|---|---|---|
| Price | $43.55 | $16.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $43.40 | $30.17 |
| AVG Volume (30 Days) | 103.6K | ★ 948.2K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | 16.06 | ★ 48.04 |
| EPS | ★ 3.83 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | $11.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.62 | $3.17 |
| 52 Week High | $44.85 | $26.95 |
| Indicator | FMBH | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 60.42 | 58.92 |
| Support Level | $42.05 | $16.15 |
| Resistance Level | $44.46 | $18.73 |
| Average True Range (ATR) | 0.82 | 0.94 |
| MACD | 0.10 | 0.29 |
| Stochastic Oscillator | 66.15 | 87.73 |
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.